BACKGROUND: We investigated the characteristics of synchronous and metachronous gastric cancer in patients with colorectal cancer. METHODS: We reviewed 8,680 patients who underwent operations for primary sporadic colorectal cancer from 1989 to 2008. Synchronous gastric cancer was defined as gastric cancer diagnosed within 6 months of a colorectal cancer diagnosis. Gastric cancer diagnosed more than 6 months before or after colorectal cancer was defined as metachronous. RESULTS: The incidences of synchronous and metachronous gastric cancer were 0.93 and 1.4%, respectively (combined 2.4%). The standardized incidence ratio was 1.199 (95% confidence interval [CI] = 1.005-1.420) when the patients with premetachronous gastric cancer were excluded. Patients with synchronous and metachronous gastric cancer were 5 years older on average compared to the control population without gastric cancer. In addition, multivariate analysis revealed an odds ratio (OR) of 3.6 for being male, OR = 2 for positive family history of solid tumors, OR = 2.2 for colonic lesion, and OR = 4 for MSH2 expression loss compared to patients without gastric cancer. Patients with postmetachronous gastric cancer (when compared to synchronous and premetachronous gastric cancer), a preoperative CEA level of less than 6 ng/ml, and a relatively early stage of colorectal cancer had significantly higher overall (p = 0.016, 0.007, and 0.004, respectively) and disease-free survival rates (p = 0.046, 0.003, and 0.004, respectively), only on univariate analysis. Lymphovascular invasion of colorectal cancer and an advanced stage of gastric cancer were independent poor prognostic factors for both overall (p = 0.018) and disease-free survival (p = 0.028). CONCLUSIONS: Gastric cancer surveillance is recommended for patients with colorectal cancer, especially when the patient is old and male, has a positive family history of solid tumors, has a colonic lesion, or lacks MSH2 expression.
BACKGROUND: We investigated the characteristics of synchronous and metachronous gastric cancer in patients with colorectal cancer. METHODS: We reviewed 8,680 patients who underwent operations for primary sporadic colorectal cancer from 1989 to 2008. Synchronous gastric cancer was defined as gastric cancer diagnosed within 6 months of a colorectal cancer diagnosis. Gastric cancer diagnosed more than 6 months before or after colorectal cancer was defined as metachronous. RESULTS: The incidences of synchronous and metachronous gastric cancer were 0.93 and 1.4%, respectively (combined 2.4%). The standardized incidence ratio was 1.199 (95% confidence interval [CI] = 1.005-1.420) when the patients with premetachronous gastric cancer were excluded. Patients with synchronous and metachronous gastric cancer were 5 years older on average compared to the control population without gastric cancer. In addition, multivariate analysis revealed an odds ratio (OR) of 3.6 for being male, OR = 2 for positive family history of solid tumors, OR = 2.2 for colonic lesion, and OR = 4 for MSH2 expression loss compared to patients without gastric cancer. Patients with postmetachronous gastric cancer (when compared to synchronous and premetachronous gastric cancer), a preoperative CEA level of less than 6 ng/ml, and a relatively early stage of colorectal cancer had significantly higher overall (p = 0.016, 0.007, and 0.004, respectively) and disease-free survival rates (p = 0.046, 0.003, and 0.004, respectively), only on univariate analysis. Lymphovascular invasion of colorectal cancer and an advanced stage of gastric cancer were independent poor prognostic factors for both overall (p = 0.018) and disease-free survival (p = 0.028). CONCLUSIONS:Gastric cancer surveillance is recommended for patients with colorectal cancer, especially when the patient is old and male, has a positive family history of solid tumors, has a colonic lesion, or lacks MSH2 expression.
Authors: Faruque Ahmed; Marc T Goodman; Carol Kosary; Bernardo Ruiz; Xiao-Cheng Wu; Vivien W Chen; Catherine N Correa Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: Jin C Kim; Young K Cho; Seon A Roh; Chang S Yu; Gyungyub Gong; Se J Jang; Seon Y Kim; Yong S Kim Journal: Cancer Sci Date: 2008-04-16 Impact factor: 6.716
Authors: S B Lim; S Y Jeong; H S Choi; D K Sohn; C W Hong; K H Jung; H J Chang; J G Park; I J Choi; C G Kim Journal: Int J Colorectal Dis Date: 2007-08-28 Impact factor: 2.571
Authors: H R Yun; L J Yi; Y K Cho; J H Park; Y B Cho; S H Yun; H C Kim; H K Chun; W Y Lee Journal: Int J Colorectal Dis Date: 2008-09-17 Impact factor: 2.571
Authors: A Horii; S Nakatsuru; Y Miyoshi; S Ichii; H Nagase; Y Kato; A Yanagisawa; Y Nakamura Journal: Cancer Res Date: 1992-06-01 Impact factor: 12.701
Authors: Meira Epplein; Michael Pawlita; Angelika Michel; Richard M Peek; Qiuyin Cai; William J Blot Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-09-17 Impact factor: 4.254